UNSPSC 51273010: Sufentanil

This classification denotes an opioid receptor agonist and opioid with the molecular formula C22H30N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AFE2YW0IIZ, chemically known as propanamide, n-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-n-phenyl- but generally known as sufentanil, which bears US NIH Compound Identifier 41693. European Medicines Agency schedules Sufentanil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10671MIG.

UNSPSC 51273010 Sufentanil is a Commodity code that identifies a specific opioid pharmaceutical product, yet recent state and local solicitations tagged under this code show minimal direct purchasing of sufentanil itself. Instead, the posted opportunities reflect broader pharmaceutical procurement frameworks—naloxone and drug deactivation systems for community health, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals through cooperative purchasing. The code sees activity from health departments, state human services agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. When state and local bodies do procure sufentanil, it is typically as part of a larger pharmaceutical supply contract rather than as a standalone item, with vendors required to maintain cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, proper insurance coverage (including commercial general liability and professional liability), and FDA clearance. Pricing is typically negotiated through net pricing models or WAC-minus structures, and vendors must distribute through authorized wholesalers and maintain electronic data interchange (EDI) capability.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with electronic bidding required and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission released RFI HHS0017013 (April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program serving state employee health plans outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness and 25 percent on administrative compliance and capability factors. The code shows modest recent activity with a mix of direct county procurement, state agency exploratory contracting, and cooperative purchasing vehicles spanning multiple states.